So prior to Cobenfy, what drugs were doing was treating the symptoms ... We continue to take decisive action to further right size our cost structure and invest in future growth.

The firm’s Cobenfy drug for schizophrenia is the first of its ... in capital expenditures in 2024 to build a data center the size of Manhattan. Overall, Meta Platforms, Inc (NASDAQ:META ...

Top stock picks for capital appreciation and outperformance, with a focus on profits, dividends, and long-term viability.

Therefore, its track record of successful drug development and commercialization ... of Bristol-Myers Squibb Company (NYSE:BMY)’s COBENFY, which continues to demonstrate strong sales momentum ...

Bristol Myers Squibb clocked $10 million in sales for new schizophrenia drug Cobenfy in the fourth quarter of 2024, with the ...

Cobenfy, the main asset acquired through Bristol Myers’ $14 billion purchase of Karuna, had $10 million in sales in the ...

Cobenfy comes as a capsule. It received Food and Drug Administration approval on Sept. 26 as a treatment for schizophrenia, then launched onto the U.S. market in late October. By Bristol Myers ...

As per the Brain and Behavior Research Foundation, it combines two compounds called xanomeline and trospium chloride. This is ...

Bristol Myers Squibb will make even deeper cuts to its organization to enhance efficiencies as it faces the 2028 loss of ...

The new drug Cobenfy, formerly known as KarXT, is manufactured by Bristol Myers Squibb, a global biopharmaceutical company. The drug became available by prescription in retail pharmacies across ...

The U.S. Food and Drug Administration has approved a new non-opioid pain medication developed by Boston-based Vertex Pharmaceuticals. The drug, which is called suzetrigine and will be sold under ...